ResMed (RMD) PT Lowered to $248 at Piper Sandler Following 'Mixed FQ3 Print'
Tweet Send to a Friend
Piper Sandler analyst Adam Maeder lowered the price target on ResMed (NYSE: RMD) to $248.00 (from $260.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
